NKCx Histopathological outcome* within 12 months after cervix cytology in 2024
088 Region Stockholm

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 497 16.6% 252 8.4% 135 4.5% 1 0.0% . . 5 0.2% 2104 70.3% 2994 100.0%
ASCUS 970 42.0% 699 30.3% 476 20.6% 7 0.3% 5 0.2% 15 0.6% 138 6.0% 2310 100.0%
LSIL 434 28.9% 557 37.1% 413 27.5% . . 3 0.2% 6 0.4% 88 5.9% 1501 100.0%
Atypical glandular cells/AGC 11 29.7% 6 16.2% 12 32.4% 3 8.1% 2 5.4% 2 5.4% 1 2.7% 37 100.0%
Unclear atypia 229 50.1% 124 27.1% 59 12.9% 6 1.3% 2 0.4% 2 0.4% 35 7.7% 457 100.0%
ASC-H 88 21.4% 80 19.4% 223 54.1% 6 1.5% 5 1.2% 2 0.5% 8 1.9% 412 100.0%
HSIL 42 8.5% 49 9.9% 370 74.6% 7 1.4% 14 2.8% 1 0.2% 13 2.6% 496 100.0%
Suspected Adenocarcinom 1 10.0% . . 2 20.0% 3 30.0% 4 40.0% . . . . 10 100.0%
Squamous cell cancer . . . . 6 60.0% . . 4 40.0% . . . . 10 100.0%
Totalt 2272 27.6% 1767 21.5% 1696 20.6% 33 0.4% 39 0.5% 33 0.4% 2387 29.0% 8227 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the
category Cancer:
M80703, M81403